Free Trial
→ Trump wipes out trillions overnight… (From Porter & Company) (Ad) Buy GSK Stock  Free GSK Stock Alerts

GSK (GSK) Financials

GSK logo
$39.02 -0.05 (-0.12%)
As of 11:05 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for GSK

Annual Income Statements for GSK

This table shows GSK's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 1,125 2,070 4,616 6,155 7,851 5,920 18,062 6,280 3,224
Consolidated Net Income / (Loss)		 1,310 2,930 5,155 6,981 8,724 6,880 18,865 6,764 3,695
Net Income / (Loss) Continuing Operations		 1,310 2,930 5,155 6,981 6,969 4,747 5,943 6,764 3,695
Total Pre-Tax Income 		2,392 4,762 6,115 8,243 7,061 4,859 6,797 7,727 4,354
Total Operating Income		 3,206 5,521 6,985 9,224 8,166 5,882 7,769 8,595 5,035
Total Gross Profit		 22,948 26,807 26,219 29,007 22,432 22,320 23,876 27,733 27,957
Total Revenue		 34,411 40,778 39,265 44,727 33,261 33,340 35,415 38,647 39,286
Operating Revenue		 34,411 40,778 39,265 - 33,261 33,340 35,415 38,647 39,286
Total Cost of Revenue		 11,462 13,971 13,047 15,719 10,829 11,020 11,538 10,914 11,329
Operating Cost of Revenue		 11,462 13,971 13,047 15,719 10,829 11,020 11,538 10,914 11,329
Total Operating Expenses		 20,234 21,767 19,614 20,249 14,705 17,001 17,023 20,351 23,715
Selling, General & Admin Expense		 11,556 13,066 12,632 15,109 10,157 9,545 10,111 11,959 13,792
Research & Development Expense		 4,476 6,047 4,960 6,053 6,546 6,776 6,628 7,930 8,015
Other Operating Expenses / (Income)		 4,201 2,654 2,023 -913 -1,998 680 284 463 1,916
Other Special Charges / (Income)		 - - - - - - 0.00 -1.27 -7.51
Total Other Income / (Expense), net		 -322 -278 -489 -515 -666 -412 -57 345 111
Interest Expense		 908 992 1,017 1,208 1,194 1,038 1,062 1,009 838
Interest & Investment Income		 89 88 103 130 44 19 92 147 153
Other Income / (Expense), net		 497 625 424 563 483 608 913 1,208 796
Income Tax Expense		 1,082 1,832 961 1,263 92 112 854 963 659
Net Income / (Loss) Discontinued Operations		 - - - - 1,755 2,133 12,922 0.00 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -185 -861 -539 -826 -873 -960 -803 -484 -471
Basic Earnings per Share		 $0.19 $0.42 $0.74 $0.94 $1.97 $1.10 $5.82 $3.10 $1.58
Weighted Average Basic Shares Outstanding		 - - 5.38B 5.38B 5.39B 5.39B 4.31B 4.31B 4.31B
Diluted Earnings per Share		 $0.19 $0.42 $0.73 $0.93 $2.54 $1.61 $11.99 $3.06 $1.56
Weighted Average Diluted Shares Outstanding		 - - 5.38B 5.38B 5.39B 5.39B 4.31B 4.31B 4.31B
Weighted Average Basic & Diluted Shares Outstanding		 - - 5.38B 5.38B 5.39B 5.39B 4.31B 4.31B 4.31B

Quarterly Income Statements for GSK

No quarterly income statements for GSK are available.

Annual Cash Flow Statements for GSK

This table details how cash moves in and out of GSK's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 12,796 -1,436 -1,223 610 1,095 -10,781 -14,351 -659 -596 750
Net Cash From Operating Activities		 12,796 8,016 9,345 10,728 10,627 6,551 -4,821 8,941 8,624 8,206
Net Cash From Continuing Operating Activities		 12,796 8,016 9,345 10,728 10,627 6,551 -4,821 8,012 8,624 8,206
Net Income / (Loss) Continuing Operations		 12,796 1,310 2,930 5,155 6,981 0.00 0.00 5,943 6,764 3,695
Consolidated Net Income / (Loss)		 12,796 1,310 2,930 5,155 6,981 - - 5,943 6,764 3,695
Non-Cash Adjustments To Reconcile Net Income		 - 8,691 8,226 7,263 5,650 5,909 -2,912 3,651 3,553 6,148
Changes in Operating Assets and Liabilities, net		 - -1,985 -1,810 -1,689 -2,004 642 -1,909 -1,582 -1,692 -1,636
Net Cash From Discontinued Operating Activities		 - - - - - - - 929 0.00 0.00
Net Cash From Investing Activities		 0.00 -1,566 -1,949 -1,978 -7,094 -1,284 -1,104 -10,594 -2,033 -1,539
Net Cash From Continuing Investing Activities		 0.00 -1,462 -1,934 -1,978 -2,487 -1,284 -1,104 -6,016 -2,033 -1,539
Purchase of Property, Plant & Equipment		 - -2,059 -2,975 -1,712 -2,866 -1,351 -1,283 -2,727 -2,987 -3,734
Acquisitions		 - 21 0.00 -13 - 0.00 0.00 -3,754 -1,857 -1,008
Purchase of Investments		 - -118 -108 -969 -342 - - -174 -157 -183
Sale of Property, Plant & Equipment		 - 470 444 540 661 67 178 413 51 245
Divestitures		 - 89 381 33 - - - -52 62 -23
Sale and/or Maturity of Investments		 - 136 359 246 101 - - 372 2,496 3,142
Net Cash From Discontinued Investing Activities		 - - - - - - - -4,578 0.00 0.00
Net Cash From Financing Activities		 0.00 -7,887 -8,619 -8,139 -2,438 -16,048 -8,425 994 -7,188 -5,917
Net Cash From Continuing Financing Activities		 0.00 -9,045 -7,730 -8,243 -6,539 -16,048 -8,425 -11,172 -7,188 -5,917
Repayment of Debt		 - -1,993 -4,647 -3,645 -6,982 -5,105 -3,110 -9,321 -4,107 -3,096
Payment of Dividends		 - -6,643 -6,329 -5,729 -5,720 -6,035 -5,721 -4,187 -2,863 -3,060
Issuance of Debt		 - 0.00 3,017 12,916 6,352 -4,908 406 1,238 284 1,346
Issuance of Common Equity		 - 110 76 94 68 - - 30 13 25
Other Financing Activities, net		 - -519 154 -11,879 -257 - - 464 435 173
Net Cash From Discontinued Financing Activities		 - - - - - - - 12,166 0.00 0.00

Quarterly Cash Flow Statements for GSK

No quarterly cash flow statements for GSK are available.

Annual Balance Sheets for GSK

This table presents GSK's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 72,888 76,165 73,975 105,598 109,845 106,789 72,638 75,190 74,454
Total Current Assets		 20,616 21,489 21,565 25,827 27,652 25,210 25,083 23,758 21,282
Cash & Equivalents		 6,041 5,178 4,935 6,237 8,593 5,770 4,496 3,741 4,846
Short-Term Investments		 - 92 240 558 208 254 229 166 136
Accounts Receivable		 7,434 8,105 8,183 9,543 9,494 10,611 8,518 9,411 8,559
Inventories, net		 6,294 7,507 6,976 9,037 8,334 7,807 6,215 7,103 7,098
Current Deferred & Refundable Income Taxes		 279 349 292 347 916 656 489 475 612
Plant, Property, & Equipment, net		 12,288 14,671 14,088 13,712 13,897 13,408 10,788 11,494 11,553
Plant, Property & Equipment, gross		 12,288 14,671 14,088 13,712 13,897 13,408 10,788 11,494 11,553
Total Noncurrent Assets		 45,628 40,005 39,687 66,059 68,296 68,171 36,767 39,938 41,619
Long-Term Investments		 1,649 1,487 1,985 2,850 4,676 2,989 1,861 1,519 1,498
Goodwill		 7,359 7,746 7,375 13,995 14,472 14,245 8,509 8,679 8,742
Intangible Assets		 23,164 23,724 21,915 41,018 40,731 40,607 17,292 18,819 19,426
Noncurrent Deferred & Refundable Income Taxes		 5,396 5,128 4,952 5,428 5,855 7,044 6,833 7,708 8,460
Other Noncurrent Operating Assets		 7,795 1,920 3,460 2,768 2,562 3,286 2,272 3,213 3,492
Total Liabilities & Shareholders' Equity		 77,965 67,827 73,975 105,598 109,845 106,789 72,638 66,701 65,338
Total Liabilities		 66,765 71,451 69,297 81,274 81,428 77,977 60,445 58,885 58,069
Total Current Liabilities		 21,703 35,892 28,653 31,868 30,248 31,955 27,548 26,847 27,167
Short-Term Debt		 5,094 3,816 8,446 9,167 5,087 4,861 4,773 3,585 2,941
Accounts Payable		 14,760 28,328 18,815 19,795 21,633 23,698 19,641 21,138 19,201
Current Deferred & Payable Income Tax Liabilities		 1,610 1,344 - 833 744 660 569 - 880
Other Current Liabilities		 239 950 162 2,072 2,783 2,735 2,565 145 2,677
Total Noncurrent Liabilities		 47,660 35,559 40,644 49,406 51,180 46,023 32,898 32,038 30,902
Long-Term Debt		 18,087 19,269 32,767 31,259 31,992 27,774 20,573 19,376 18,327
Noncurrent Deferred & Payable Income Tax Liabilities		 2,386 2,441 1,819 5,299 5,157 5,044 502 492 478
Noncurrent Employee Benefit Liabilities		 5,046 4,781 3,981 4,581 4,985 4,203 3,115 2,982 2,334
Other Noncurrent Operating Liabilities		 22,141 2,184 2,077 8,267 9,046 9,003 8,708 2,041 2,115
Total Equity & Noncontrolling Interests		 8,601 4,713 4,678 24,324 28,418 28,812 12,193 16,305 16,385
Total Preferred & Common Equity		 3,865 -92 4,817 39,437 28,418 20,324 12,799 17,008 17,117
Preferred Stock		 - 4,078 3,938 4,206 4,481 4,456 4,154 4,398 4,349
Total Common Equity		 3,865 -4,170 879 10,907 15,441 15,868 8,645 12,610 12,769
Common Stock		 1,656 1,814 1,714 1,784 1,838 1,818 1,627 1,718 1,688
Retained Earnings		 -6,652 -8,750 -3,460 6,003 9,225 10,724 5,269 9,225 9,761
Other Equity Adjustments		 8,862 2,765 2,626 3,121 4,377 3,325 1,749 1,668 1,320
Noncontrolling Interest		 4,736 4,805 -139 9,212 8,496 8,487 -606 -703 -732

Quarterly Balance Sheets for GSK

This table presents GSK's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q4 2023 Q4 2024
Period end date 12/31/2022 12/31/2023 12/31/2024
Total Assets		 72,638 75,190 74,454
Total Current Assets		 25,083 23,758 21,282
Cash & Equivalents		 4,496 3,741 4,846
Short-Term Investments		 229 166 136
Accounts Receivable		 8,518 9,411 8,559
Inventories, net		 6,215 7,103 7,098
Current Deferred & Refundable Income Taxes		 489 475 612
Plant, Property, & Equipment, net		 10,788 11,494 11,553
Plant, Property & Equipment, gross		 10,788 11,494 11,553
Total Noncurrent Assets		 36,767 39,938 41,619
Long-Term Investments		 1,861 1,519 1,498
Goodwill		 8,509 8,679 8,742
Intangible Assets		 17,292 18,819 19,426
Noncurrent Deferred & Refundable Income Taxes		 6,833 7,708 8,460
Other Noncurrent Operating Assets		 2,272 3,213 3,492
Total Liabilities & Shareholders' Equity		 72,638 66,701 65,338
Total Liabilities		 60,445 58,885 58,069
Total Current Liabilities		 27,548 26,847 27,167
Short-Term Debt		 4,773 3,585 2,941
Accounts Payable		 19,641 21,138 19,201
Current Deferred & Payable Income Tax Liabilities		 569 - 880
Other Current Liabilities		 2,565 145 2,677
Total Noncurrent Liabilities		 32,898 32,038 30,902
Long-Term Debt		 20,573 19,376 18,327
Noncurrent Deferred & Payable Income Tax Liabilities		 502 492 478
Noncurrent Employee Benefit Liabilities		 3,115 2,982 2,334
Other Noncurrent Operating Liabilities		 8,708 2,041 2,115
Total Equity & Noncontrolling Interests		 12,193 16,305 16,385
Total Preferred & Common Equity		 12,799 17,008 17,117
Preferred Stock		 4,154 4,398 4,349
Total Common Equity		 8,645 12,610 12,769
Common Stock		 1,627 1,718 1,688
Retained Earnings		 5,269 9,225 9,761
Other Equity Adjustments		 1,749 1,668 1,320
Noncontrolling Interest		 -606 -703 -732

Annual Metrics and Ratios for GSK

This table displays calculated financial ratios and metrics derived from GSK's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 18.50% -3.71% 13.91% -25.64% 0.24% 6.22% 9.13% 1.65%
EBITDA Growth		 0.00% 118.94% 66.00% 20.55% 32.09% -11.63% -24.97% 33.79% 12.91% -40.52%
EBIT Growth		 0.00% 118.94% 66.00% 20.55% 32.09% -11.63% -24.97% 33.79% 12.91% -40.52%
NOPAT Growth		 0.00% 108.98% 93.50% 73.32% 32.66% 3.19% -28.70% 18.22% 10.75% -43.20%
Net Income Growth		 0.00% 0.00% 123.61% 75.92% 35.43% 24.98% -21.14% 174.22% -64.15% -45.37%
EPS Growth		 0.00% -92.94% 125.16% 135.16% 27.02% 24.98% -21.14% 643.49% -74.52% -49.03%
Operating Cash Flow Growth		 0.00% -37.35% 16.58% 14.80% -0.94% -38.35% -173.59% 285.46% -3.54% -4.85%
Free Cash Flow Firm Growth		 0.00% 0.00% 91.40% 259.60% -602.20% 173.29% -52.11% 523.83% -118.40% 156.82%
Invested Capital Growth		 0.00% 0.00% 22.22% 9.82% 71.98% -5.61% 0.79% -50.66% 52.87% 2.01%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 66.69% 65.74% 66.77% 64.85% 67.44% 66.95% 67.42% 71.76% 71.16%
EBITDA Margin		 0.00% 10.76% 15.07% 18.87% 21.88% 26.00% 19.46% 24.52% 25.37% 14.84%
Operating Margin		 0.00% 9.32% 13.54% 17.79% 20.62% 24.55% 17.64% 21.94% 22.24% 12.82%
EBIT Margin		 0.00% 10.76% 15.07% 18.87% 21.88% 26.00% 19.46% 24.52% 25.37% 14.84%
Profit (Net Income) Margin		 0.00% 3.81% 7.19% 13.13% 15.61% 26.23% 20.63% 53.27% 17.50% 9.41%
Tax Burden Percent		 -65.45% 54.77% 61.53% 84.29% 84.68% 123.56% 141.59% 277.56% 87.53% 84.87%
Interest Burden Percent		 100.00% 64.61% 77.47% 82.53% 84.23% 81.64% 74.87% 78.29% 78.82% 74.66%
Effective Tax Rate		 0.00% 45.23% 38.47% 15.71% 15.32% 1.30% 2.31% 12.56% 12.47% 15.13%
Return on Invested Capital (ROIC)		 0.00% 14.74% 12.83% 19.27% 17.96% 15.08% 11.03% 17.39% 23.05% 10.72%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 8.89% 10.48% 16.44% 15.10% 17.53% 15.85% 82.41% 18.92% 8.26%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 15.73% 31.18% 90.50% 30.18% 18.01% 13.02% 74.63% 24.42% 11.89%
Return on Equity (ROE)		 0.00% 30.47% 44.01% 109.77% 48.14% 33.08% 24.04% 92.02% 47.47% 22.61%
Cash Return on Invested Capital (CROIC)		 0.00% -185.26% -7.17% 9.91% -34.97% 20.85% 10.24% 85.23% -18.77% 8.73%
Operating Return on Assets (OROA)		 0.00% 5.08% 8.25% 9.87% 10.90% 8.03% 5.99% 9.68% 13.26% 7.79%
Return on Assets (ROA)		 0.00% 1.80% 3.93% 6.87% 7.77% 8.10% 6.35% 21.03% 9.15% 4.94%
Return on Common Equity (ROCE)		 0.00% 13.69% -1.01% -38.47% 19.56% 16.53% 13.15% 55.01% 35.41% 17.55%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 33.90% -3,189.71% 110.19% 17.70% 30.70% 33.85% 147.40% 39.77% 21.59%
Net Operating Profit after Tax (NOPAT)		 -19,551 1,756 3,397 5,888 7,811 8,060 5,746 6,793 7,524 4,273
NOPAT Margin		 0.00% 5.10% 8.33% 15.00% 17.46% 24.23% 17.24% 19.18% 19.47% 10.88%
Net Nonoperating Expense Percent (NNEP)		 0.00% 5.85% 2.36% 2.84% 2.86% -2.45% -4.82% -65.02% 4.13% 2.46%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 18.10% 19.16% 11.35%
Cost of Revenue to Revenue		 0.00% 33.31% 34.26% 33.23% 35.15% 32.56% 33.05% 32.58% 28.24% 28.84%
SG&A Expenses to Revenue		 0.00% 33.58% 32.04% 32.17% 33.78% 30.54% 28.63% 28.55% 30.95% 35.11%
R&D to Revenue		 0.00% 13.01% 14.83% 12.63% 13.53% 19.68% 20.32% 18.72% 20.52% 20.40%
Operating Expenses to Revenue		 0.00% 58.80% 53.38% 49.95% 45.27% 44.21% 50.99% 48.07% 52.66% 60.36%
Earnings before Interest and Taxes (EBIT)		 -19,551 3,703 6,147 7,409 9,787 8,649 6,489 8,682 9,803 5,831
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -19,551 3,703 6,147 7,409 9,787 8,649 6,489 8,682 9,803 5,831
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 91.19 9.51 5.43 6.82 9.75 5.97 5.65
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 0.00 0.00 0.00 2.04 2.32 2.52 3.25 2.38 1.95 1.84
Price to Earnings (P/E)		 0.00 0.00 0.00 17.37 16.85 10.68 18.29 4.67 11.99 22.37
Dividend Yield		 7.93% 7.39% 8.06% 7.15% 5.29% 6.58% 5.47% 5.23% 4.02% 5.87%
Earnings Yield		 0.00% 0.00% 0.00% 5.76% 5.94% 9.36% 5.47% 21.42% 8.34% 4.47%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 3.44 2.69 2.32 2.77 4.13 2.45 2.25
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 2.80 3.31 3.62 4.34 3.01 2.50 2.30
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 14.85 15.11 13.93 22.32 12.28 9.85 15.53
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 14.85 15.11 13.93 22.32 12.28 9.85 15.53
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 18.68 18.94 14.94 25.20 15.70 12.83 21.19
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 10.25 13.92 18.38 0.00 11.93 11.19 11.03
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 36.32 0.00 10.81 27.13 3.20 0.00 26.01
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 2.70 4.90 7.10 1.66 1.30 1.13 2.08 1.41 1.30
Long-Term Debt to Equity		 0.00 2.10 4.09 5.52 1.29 1.13 0.96 1.69 1.19 1.12
Financial Leverage		 0.00 1.77 2.98 5.51 2.00 1.03 0.82 0.91 1.29 1.44
Leverage Ratio		 0.00 8.47 11.19 15.99 6.19 4.08 3.79 4.38 5.19 4.58
Compound Leverage Factor		 0.00 5.48 8.67 13.19 5.22 3.33 2.83 3.43 4.09 3.42
Debt to Total Capital		 0.00% 72.94% 83.05% 87.65% 62.43% 56.61% 53.11% 67.52% 58.48% 56.48%
Short-Term Debt to Total Capital		 0.00% 16.03% 13.73% 19.48% 14.16% 7.77% 7.91% 12.71% 9.13% 7.81%
Long-Term Debt to Total Capital		 0.00% 56.91% 69.32% 68.17% 48.28% 48.84% 45.20% 54.80% 49.35% 48.67%
Preferred Equity to Total Capital		 0.00% 0.00% 14.67% 10.39% 6.50% 6.84% 7.25% 11.07% 11.20% 11.55%
Noncontrolling Interests to Total Capital		 0.00% 14.90% 17.29% -0.37% 14.23% 12.97% 13.81% -1.62% -1.79% -1.95%
Common Equity to Total Capital		 0.00% 12.16% -15.00% 2.32% 16.84% 23.57% 25.82% 23.03% 32.12% 33.91%
Debt to EBITDA		 0.00 6.26 3.76 4.48 4.13 4.29 5.03 2.92 2.34 3.65
Net Debt to EBITDA		 0.00 4.18 2.66 3.52 3.15 2.73 3.64 2.16 1.79 2.54
Long-Term Debt to EBITDA		 0.00 4.88 3.13 3.49 3.19 3.70 4.28 2.37 1.98 3.14
Debt to NOPAT		 0.00 13.20 6.80 5.64 5.18 4.60 5.68 3.73 3.05 4.98
Net Debt to NOPAT		 0.00 8.82 4.81 4.42 3.94 2.93 4.11 2.76 2.33 3.46
Long-Term Debt to NOPAT		 0.00 10.30 5.67 4.39 4.00 3.97 4.83 3.03 2.58 4.29
Altman Z-Score		 0.00 0.00 0.00 1.37 1.51 1.27 1.41 1.78 1.83 1.62
Noncontrolling Interest Sharing Ratio		 0.00% 55.06% 102.29% 135.04% 59.36% 50.04% 45.29% 40.22% 25.41% 22.36%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 0.00 0.95 0.60 0.75 0.81 0.91 0.79 0.91 0.88 0.78
Quick Ratio		 0.00 0.62 0.37 0.47 0.51 0.60 0.52 0.48 0.50 0.50
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -22,071 -1,897 3,028 -15,209 11,146 5,338 33,298 -6,126 3,481
Operating Cash Flow to CapEx		 0.00% 504.43% 369.35% 915.33% 481.97% 510.32% -436.55% 386.38% 293.75% 235.25%
Free Cash Flow to Firm to Interest Expense		 0.00 -24.30 -1.91 2.98 -12.58 9.34 5.14 31.37 -6.07 4.16
Operating Cash Flow to Interest Expense		 0.00 8.83 9.43 10.55 8.79 5.49 -4.64 8.42 8.55 9.80
Operating Cash Flow Less CapEx to Interest Expense		 0.00 7.08 6.87 9.40 6.97 4.41 -5.71 6.24 5.64 5.63
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.47 0.55 0.52 0.50 0.31 0.31 0.39 0.52 0.53
Accounts Receivable Turnover		 0.00 4.63 5.25 4.82 5.05 3.49 3.32 3.70 4.31 4.37
Inventory Turnover		 0.00 1.82 2.02 1.70 1.87 1.25 1.37 1.65 1.64 1.60
Fixed Asset Turnover		 0.00 2.80 3.03 2.73 3.22 2.41 2.44 2.93 3.47 3.41
Accounts Payable Turnover		 0.00 0.78 0.65 0.56 0.83 0.52 0.49 0.53 0.54 0.56
Days Sales Outstanding (DSO)		 0.00 78.86 69.55 75.71 72.33 104.46 110.06 98.58 84.66 83.48
Days Inventory Outstanding (DIO)		 0.00 200.43 180.28 214.23 195.57 292.75 267.30 221.78 222.69 228.77
Days Payable Outstanding (DPO)		 0.00 470.00 562.85 646.40 437.44 698.20 750.71 685.48 681.87 649.83
Cash Conversion Cycle (CCC)		 0.00 -190.72 -313.02 -356.47 -169.54 -300.99 -373.35 -365.12 -374.52 -337.58
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.00 23,826 29,121 31,981 55,000 51,913 52,322 25,817 39,466 40,259
Invested Capital Turnover		 0.00 2.89 1.54 1.29 1.03 0.62 0.64 0.91 1.18 0.99
Increase / (Decrease) in Invested Capital		 0.00 23,826 5,295 2,860 23,019 -3,087 409 -26,505 13,649 792
Enterprise Value (EV)		 0.00 0.00 0.00 110,001 147,902 120,443 144,819 106,629 96,516 90,533
Market Capitalization		 0.00 0.00 0.00 80,157 103,704 83,864 108,252 84,322 75,287 72,128
Book Value per Share		 $0.00 $0.00 $0.00 $0.16 $2.03 $2.87 $2.95 $1.60 $2.92 $2.96
Tangible Book Value per Share		 $0.00 $0.00 $0.00 ($5.29) ($8.20) ($7.39) ($7.24) ($3.18) ($3.45) ($3.57)
Total Capital		 0.00 31,783 27,799 37,883 64,750 65,497 61,447 37,539 39,265 37,653
Total Debt		 0.00 23,181 23,085 33,205 40,426 37,079 32,635 25,346 22,960 21,268
Total Long-Term Debt		 0.00 18,087 19,269 25,825 31,259 31,992 27,774 20,573 19,376 18,327
Net Debt		 0.00 15,490 16,328 26,045 30,780 23,602 23,622 18,759 17,534 14,789
Capital Expenditures (CapEx)		 0.00 1,589 2,530 1,172 2,205 1,284 1,104 2,314 2,936 3,488
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -2,034 -15,857 -4,883 -3,669 -6,310 -7,907 -2,418 -3,411 -7,926
Debt-free Net Working Capital (DFNWC)		 0.00 4,007 -10,587 292 3,126 2,491 -1,883 2,308 496 -2,944
Net Working Capital (NWC)		 0.00 -1,087 -14,403 -7,088 -6,041 -2,596 -6,745 -2,465 -3,089 -5,885
Net Nonoperating Expense (NNE)		 -32,347 445 467 733 830 -664 -1,133 -12,072 760 578
Net Nonoperating Obligations (NNO)		 0.00 15,225 24,408 27,303 30,676 23,496 23,510 13,624 23,162 23,874
Total Depreciation and Amortization (D&A)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -5.91% -38.89% -12.44% -8.20% -18.97% -23.72% -6.83% -8.83% -20.17%
Debt-free Net Working Capital to Revenue		 0.00% 11.64% -25.96% 0.74% 6.99% 7.49% -5.65% 6.52% 1.28% -7.49%
Net Working Capital to Revenue		 0.00% -3.16% -35.32% -18.05% -13.51% -7.81% -20.23% -6.96% -7.99% -14.98%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 $0.41 $0.75 $0.95 $1.17 $0.00 $4.49 $1.22 $1.58
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 0.00 5.29B 5.30B 5.30B 0.00 4.31B 4.31B 4.31B
Adjusted Diluted Earnings per Share		 $0.00 $0.00 $0.41 $0.74 $0.94 $1.16 $0.00 $10.67 $1.20 $1.56
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 0.00 5.29B 5.30B 5.30B 0.00 4.31B 4.31B 4.31B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 0.00 5.29B 5.30B 5.30B 0.00 4.31B 4.31B 4.31B
Normalized Net Operating Profit after Tax (NOPAT)		 -13,686 1,756 3,397 5,888 7,811 8,060 5,746 6,793 7,522 4,267
Normalized NOPAT Margin		 0.00% 5.10% 8.33% 15.00% 17.46% 24.23% 17.24% 19.18% 19.46% 10.86%
Pre Tax Income Margin		 0.00% 6.95% 11.68% 15.57% 18.43% 21.23% 14.57% 19.19% 19.99% 11.08%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 4.08 6.20 7.29 8.10 7.25 6.25 8.18 9.71 6.96
NOPAT to Interest Expense		 0.00 1.93 3.43 5.79 6.46 6.75 5.54 6.40 7.45 5.10
EBIT Less CapEx to Interest Expense		 0.00 2.33 3.65 6.14 6.27 6.17 5.19 6.00 6.80 2.80
NOPAT Less CapEx to Interest Expense		 0.00 0.18 0.87 4.64 4.64 5.68 4.47 4.22 4.55 0.94
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 506.97% 216.00% 111.15% 81.95% 69.18% 83.16% 22.19% 42.33% 82.82%
Augmented Payout Ratio		 0.00% 506.97% 216.00% 111.15% 81.95% 69.18% 83.16% 22.19% 42.33% 82.82%

Quarterly Metrics and Ratios for GSK

No quarterly metrics and ratios for GSK are available.

Frequently Asked Questions About GSK's Financials

When does GSK's financial year end?

According to the most recent income statement we have on file, GSK's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has GSK's net income changed over the last 8 years?

GSK's net income appears to be on an upward trend, with a most recent value of $3.69 billion in 2024, rising from $1.31 billion in 2016. The previous period was $6.76 billion in 2023. See where experts think GSK is headed by visiting GSK's forecast page.

What is GSK's operating income?
GSK's total operating income in 2024 was $5.03 billion, based on the following breakdown:
  • Total Gross Profit: $27.96 billion
  • Total Operating Expenses: $23.71 billion
How has GSK revenue changed over the last 8 years?

Over the last 8 years, GSK's total revenue changed from $34.41 billion in 2016 to $39.29 billion in 2024, a change of 14.2%.

How much debt does GSK have?

GSK's total liabilities were at $58.07 billion at the end of 2024, a 1.4% decrease from 2023, and a 13.0% decrease since 2016.

How much cash does GSK have?

In the past 8 years, GSK's cash and equivalents has ranged from $3.74 billion in 2023 to $8.59 billion in 2020, and is currently $4.85 billion as of their latest financial filing in 2024.

How has GSK's book value per share changed over the last 9 years?

Over the last 9 years, GSK's book value per share changed from 0.00 in 2015 to 2.96 in 2024, a change of 296.1%.


Related Companies

This page (NYSE:GSK) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Elon Reveals Why There Soon Won’t Be Any Money For Social Security
Elon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...
Colonial Metals | Sponsored
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Man who predicted $100K Bitcoin sees a huge run coming for another coin …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...
Weiss Ratings | Sponsored
Musk's warning signal: Prepare before the cascade begins
When Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...
InvestorPlace | Sponsored